EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats

Elham Khoshbakht, Negar Dinarvand, Hamid Yaghooti, Behrouz Taheri, Narges Mohammadtaghvaei

Research in Pharmaceutical Sciences · 2026-05 · 21 (3) · 292-304

DOI: 10.4103/rps.rps_182_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 10.05.2026. Verfasst von Elham Khoshbakht und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder worldwide, affecting approximately 25% of the global population. Peroxisome proliferator-activated receptor (PPAR) agonists play an important role in NAFLD management through modulation of lipid metabolism and insulin sensitivity. This study compared the effects of fenofibrate (PPARα agonist), pioglitazone (PPARγ agonist), and saroglitazar (dual PPARα/γ agonist) in a high-fat diet (HFD)-induced NAFLD rat model. Experimental approach: NAFLD was induced in Wistar rats by feeding a high-fat diet. Animals were assigned to control, HFD, and HFD-treated groups receiving saroglitazar (3 mg/kg), pioglitazone (30 mg/kg), or fenofibrate (100 mg/kg) for six weeks. Anthropometric parameters, serum liver enzymes, lipid profile, fasting blood glucose, and HOMA-IR were assessed. Histopathological changes were evaluated using H&E and Masson’s trichrome staining. Hepatic expression of FGF21, CPT-1, PPARa, SREBP-1c, and ACC was analyzed by quantitative RT-PCR. Findings/Results: All three PPAR agonists significantly improved hepatic steatosis, inflammation, and fibrosis compared with the HFD group, despite variability in biochemical and metabolic parameters. Among the treatments, saroglitazar demonstrated the most pronounced histological improvement, although systemic metabolic improvements were comparable among all three agents. Conclusion and implications: Fenofibrate, pioglitazone, and saroglitazar exert beneficial effects on NAFLD progression through partially distinct mechanisms. Dual PPARα/γ activation appears to preferentially enhance hepatic histological outcomes, supporting the therapeutic relevance of saroglitazar in NAFLD.

Schlagwörter

Stichwörter der Autor:innen

FenofibrateNAFLDNASHPioglitazoneSaroglitazar.

Autor:innen und Institutionen

  • Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Department of Medical Biotechnology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Department of Laboratory Sciences, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zitieren

APA

Khoshbakht, E., Dinarvand, N., Yaghooti, H., Taheri, B., & Mohammadtaghvaei, N. (2026). Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats. Research in Pharmaceutical Sciences, 21(3), 292-304. https://doi.org/10.4103/rps.rps_182_25

Vancouver

Khoshbakht E, Dinarvand N, Yaghooti H, Taheri B, Mohammadtaghvaei N. Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats. Research in Pharmaceutical Sciences. 2026;21(3):292-304. doi:10.4103/rps.rps_182_25

BibTeX
@article{Khoshbakht2026,
  author = {Khoshbakht, Elham and Dinarvand, Negar and Yaghooti, Hamid and Taheri, Behrouz and Mohammadtaghvaei, Narges},
  title = {Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats},
  journal = {Research in Pharmaceutical Sciences},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {292--304},
  doi = {10.4103/rps.rps_182_25}
}
Kostenlos starten →